# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

### FORM 8-K

# CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 29, 2014

## BioCryst Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation) 000-23186 (Commission File Number) 62-1413174 (IRS Employer Identification No.)

4505 Emperor Blvd., Suite 200 Durham, North Carolina 27703 (Address of Principal Executive Offices)

 $\begin{tabular}{ll} (919) 859-1302 \\ (Registrant's telephone number, including area code) \end{tabular}$ 

(Former Name or Former Address, if Changed Since Last Report)

e appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following s (see General Instruction A.2 below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 210.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Item 1.01. Entry into a Material Definitive Agreement.

On April 29, 2014, BioCryst Pharmaceuticals, Inc. (the "Company") and the U.S. Department of Health and Human Services ("HHS") mutually agreed to amend the Agreement dated January 3, 2007 between the Company and HHS (the "Agreement") to extend the Agreement's current expiration date of April 30, 2014 for 31 days. The new expiration date is changed to May 31, 2014. All other terms and conditions of the Agreement remain unchanged.

#### Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

10.1 Amendment #19 to the Agreement between BioCryst Pharmaceuticals, Inc. and the U.S. Department of Health and Human Services, dated April 29, 2014.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 2, 2014 BioCryst Pharmaceuticals, Inc.

By: /s/ Alane Barnes

Alane Barnes

Vice President, General Counsel, and Corporate Secretary

### EXHIBIT INDEX

Exhibit No.	<u>Description</u>
10.1	Amendment #19 to the Agreement between BioCryst Pharmaceuticals, Inc. and the U.S. Department of Health and Human Services, dated April 29, 2014.

AMENDMENT OF SOLICITATION/MODIF	CT	1. CONTRACT ID CODE			PAGE 1	OF 	PAGES 1	
2. AMENDMENT/MODIFICATION NO. )019	3. EFFECTIVE DATE See Block 16C	4. REQUISITION/PI	URCHA	ASE REQ. NO.	5. PRC	DJECT NO. (	If app	olicable)
5. ISSUED BY CODE	ASPR-BARDA		D BY (If other than Item 6) CODE ASI				BARD	DA01
ASPR-BARDA 330 INDEPENDENCE AVE SW ROOM 644-G WASHINGTON DC 20201	ASPR-BARDA 330 INDEPENDENCE AVE SW RM G644 WASHINGTON DC 20201							
3. NAME AND ADDRESS OF CONTRACTOR (No., street, county, Sta	<u> </u>	(X) 9A. AMENDMENT OF SOLICITATION NO.						
BIOCRYST PHARMACEUTICALS, INC. 4505 EMPEROR BOULEVARD, SUITE 200 DURHAM, NC 27703			9B. DATED (SEE ITEM 11)					
				10A. MODIFICATION OF C	ONTRA	CT/ORDER	NO.	
			$\times$	HHSO100200700032C				
				10B. DATED (SEE ITEM 13)				
CODE FACILITY				01/03/2007				
	M ONLY APPLIES TO AN							
$\square$ The above numbered solicitation is amended as set forth in Item 14. $\square$	Γhe hour and date specified	for receipt of Offers	is ext	ended, $\square$ is not extended.				
Offers must acknowledge receipt of this amendment prior to the hour and	l date specified in the solicit	ation or as amended, by	y one of	the following methods:				
(a) By completing items 8 and 15, and returning copies of the etter or telegram which includes a reference to the solicitation and amen. THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECTABLE STREAM SUBMITTED AND LATE SPECTABLE STREAM SUBMITTED AND LATE SPECTABLE STREAM SUBMITTED AND APPROPRIATION DATA (If required) N/A	dment numbers. FAILURE CIFIED MAY RESULT IN 1	OF YÖUR ACKNOWI REJECTION OF YOU	LEDGN R OFFI	ER. If by virtue of this amendme	HE PLA	CE DESIGN lesire to char	NATEI nge an	D FOR offer
13. THIS ITEM O	NLY APPLIES TO MODI THE CONTRACT/ORDE							
CHECK ONE  A. THIS CHANGE ORDER IS ISSUED PURSUA CONTRACT ORDER NO. IN ITEM 10A.					THE			
B. THE ABOVE NUMBERED CONTRACT/ORI			STRAT	TVE CHANGES (such as chang	jes in pay	ring office, a	pprop	riation
date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).  C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF: BILATERAL MODIFICATION AT THE MUTUAL AGREEMENT OF THE PARTIES								
D. OTHER (Specify type of modification and author								
E. IMPORTANT: Contractor □ is not, ☒ is required to sign this doc	ument and return 1	conies to the issuing	office					
14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized b				bject matter where feasible.)				
This Contract's expiration date is changed by 31 days from April 30, 201	4 to May 31, 2014.							
Except as provided herein, all terms and conditions of the document refer ISA. NAME AND TITLE OF SIGNER (Type or print)	renced in Item 9A or 10A, a			unchanged and in full force and OF CONTRACTING OFFICER		nrint)		
DA. NAME AND TITLE OF SIGNER (Type of print)		KEVIN NILLES	IILE (	OF CONTRACTING OFFICER	( 1уре ог	pi ilit)		
ISB. CONTRACTOR/OFFEROR	15C. DATE SIGNED	16B. UNITED STAT	ES OF	AMERICA		16C. DATE	SIGN	ĮED
(Signature of person authorized to sign)		(Sian	atura o	Contracting Officer)				

NSN 7540-01-152-8070 Previous edition unusable STANDARD FORM 30 (REV. 10-83) Prescribed by GSA FAR (48 CFR) 53.243